ArticleBMJ open2026
Multicentre open-label randomised controlled trial to evaluate the efficacy and safety of moderate-dose and high-dose intravenous methylprednisolone combined with plasmapheresis versus plasmapheresis alone in leptospirosis pulmonary haemorrhage syndrome: a protocol.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Corticosteroids for treatment of leptospirosis.The Cochrane database of systematic reviews · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLeptospirosis is a zoonotic infection caused by the bacterium METHODS AND ANALYSIS: This open-label, randomised controlled trial will enrol LPHS patients from four selected tertiary care hospitals in Sri Lanka. Participants will be randomly assigned to three groups in a 1:1:1 ratio to receive plasmapheresis alone, plasmapheresis with 150 mg/day methylprednisolone for 3 days or plasmapheresis with 1000 mg/day methylprednisolone for 3 days. Recruitment will consist of 28 participants to each arm of the trial. Diagnosis will be confirmed by ETHICS AND DISSEMINATION: The ethical approval was obtained from the Research Ethics Committee of the University of Sri Jayewardenepura (ERC 20/24) and the trial has been registered in the Sri Lanka Clinical Trials Registry (SLCTR/2024/037). Trial is approved by the National Medicines Regulatory Authority in Sri Lanka (NMRA/CTRD/PA4/54). Study findings will be disseminated through peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: Sri Lanka Clinical Trials Registry, Number SLCTR/2024/037.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.